View Cart  

FDA Requests New Clinical Trial for Lilly’s Liprotamase

A A
The FDA has issued a complete response letter to Eli Lilly regarding its NDA for exocrine pancreatic insufficiency (EPI) treatment liprotamase, requesting an additional clinical trial.

To View This Article:

Login

Subscribe To Drug Industry Daily